| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Urmas Roostalu, Casper B G Salinas, Ditte D Thorbek, Jacob L Skytte, Katrine Fabricius, Pernille Barkholt, Linu M John, Vanessa Isabell Jurtz, Lotte Bjerre Knudsen, Jacob Jelsing, Niels Vrang, Henrik H Hansen, Jacob Hecksher-Sørense. Quantitative whole-brain 3D imaging of tyrosine hydroxylase-labeled neuron architecture in the mouse MPTP model of Parkinson's disease. Disease models & mechanisms. vol 12. issue 11. 2020-05-28. PMID:31704726. |
parkinson's disease (pd) is a basal ganglia movement disorder characterized by progressive degeneration of the nigrostriatal dopaminergic system. |
2020-05-28 |
2023-08-13 |
mouse |
| Hailan Hu, Yihui Cui, Yan Yan. Circuits and functions of the lateral habenula in health and in disease. Nature reviews. Neuroscience. vol 21. issue 5. 2020-05-11. PMID:32269316. |
the lhb, sometimes referred to as the brain's 'antireward centre', receives inputs from diverse limbic forebrain and basal ganglia structures, and targets essentially all midbrain neuromodulatory systems, including the noradrenergic, serotonergic and dopaminergic systems. |
2020-05-11 |
2023-08-13 |
Not clear |
| Salil Patel, James J Fitzgerald, Chrystalina A Antoniade. Oculomotor effects of medical and surgical treatments of Parkinson's disease. Progress in brain research. vol 249. 2020-05-07. PMID:31325988. |
saccades-ballistic eye movements-are known to be affected by dopaminergic cell loss in the basal ganglia, caused by parkinson's disease. |
2020-05-07 |
2023-08-13 |
Not clear |
| Cuizhen Liu, Bo Cao, Rongjun Yu, Kang Si. Basal ganglia volumetric changes in psychotic spectrum disorders. Journal of affective disorders. vol 255. 2020-05-05. PMID:31153051. |
basal ganglia are particularly important for understanding the pathobiology of psychosis given their key roles in dopaminergic neurotransmission which are associated with psychotic symptoms and one of the target sites of antipsychotic drugs. |
2020-05-05 |
2023-08-13 |
Not clear |
| Himadri Shekhaar Baul, Ceera Manikandan, Dwaipayan Se. Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease. Brain research bulletin. vol 146. 2020-03-10. PMID:30664919. |
parkinson's disease (pd) is the second most prevalent neurodegenerative disease, characterized by the loss of dopaminergic neurons from substantia nigra pars compacta of basal ganglia caused due to gene mutation, misfolded protein aggregation, reactive oxygen species generation and inflammatory stress. |
2020-03-10 |
2023-08-13 |
Not clear |
| Utkarsha A Singh, Soumya Iyenga. The expression of DARPP-32 in adult male zebra finches (Taenopygia guttata). Brain structure & function. vol 224. issue 8. 2020-02-24. PMID:31473781. |
our results suggest that whereas dopamine may modulate the shell pathways at various levels of the afp, dopaminergic modulation of the core pathway occurs mainly through area x, a basal ganglia nucleus. |
2020-02-24 |
2023-08-13 |
Not clear |
| Weitong Cui, Yuxi Zhan, Xiaoru Shao, Wei Fu, Dexuan Xiao, Junyao Zhu, Xin Qin, Tianyi Zhang, Mei Zhang, Yi Zhou, Yunfeng Li. Neuroprotective and Neurotherapeutic Effects of Tetrahedral Framework Nucleic Acids on Parkinson's Disease ACS applied materials & interfaces. vol 11. issue 36. 2020-02-11. PMID:31424187. |
pd is caused by dysfunction of basal ganglia, decrease of dopaminergic neurons in substantia nigra, and abnormal accumulation of lewy bodies and lewy neurites. |
2020-02-11 |
2023-08-13 |
Not clear |
| Esther Lara-González, Mariana Duhne, Fátima Ávila-Cascajares, Silvia Cruz, José Barga. Comparison of Actions between L-DOPA and Different Dopamine Agonists in Striatal DA-Depleted Microcircuits In Vitro: Pre-Clinical Insights. Neuroscience. vol 410. 2020-01-31. PMID:31078685. |
parkinson's disease (pd) is a neurodegenerative illness presenting motor and non-motor symptoms due to the loss of dopaminergic terminals in basal ganglia, most importantly, the striatum. |
2020-01-31 |
2023-08-13 |
Not clear |
| Petra Fischer, Alek Pogosyan, Alexander L Green, Tipu Z Aziz, Jonathan Hyam, Thomas Foltynie, Patricia Limousin, Ludvic Zrinzo, Michael Samuel, Keyoumars Ashkan, Mauro Da Lio, Mariolino De Cecco, Alberto Fornaser, Peter Brown, Huiling Ta. Beta synchrony in the cortico-basal ganglia network during regulation of force control on and off dopamine. Neurobiology of disease. vol 127. 2020-01-09. PMID:30849510. |
we recorded scalp eeg and basal ganglia local field potentials in parkinson's disease patients (11 stn, 7 gpi) on and off dopaminergic medication while they performed a visually-guided force matching task using a pen on a force-sensitive graphics tablet. |
2020-01-09 |
2023-08-13 |
Not clear |
| Samira Ztaou, Marianne Amalri. Contribution of cholinergic interneurons to striatal pathophysiology in Parkinson's disease. Neurochemistry international. vol 126. 2019-12-10. PMID:30825602. |
parkinson's disease (pd) is a neurodegenerative disorder caused by the loss of nigral dopaminergic neurons innervating the striatum, the main input structure of the basal ganglia. |
2019-12-10 |
2023-08-13 |
Not clear |
| M. Amalric, C. Baunez, A. Nieoullo. Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? Behavioural pharmacology. vol 6. issue 5 And 6. 2019-11-20. PMID:11224358. |
the present study investigated the potential benefit of blocking excitatory amino acid transmission in the basal ganglia, subsequent to the inactivation of dopaminergic function of rats performing a reaction time (rt) task. |
2019-11-20 |
2023-08-12 |
rat |
| J L. Alberts, C H. Adler, M Saling, G E. Stelmac. Prehension patterns in restless legs syndrome patients. Parkinsonism & related disorders. vol 7. issue 2. 2019-11-20. PMID:11248597. |
while rls patients respond favorably to dopaminergic therapies, this study suggests that pd and rls may not share the same basal ganglia pathophysiology. |
2019-11-20 |
2023-08-12 |
human |
| Vincenzo G Fiore, Francesco Rigoli, Max-Philipp Stenner, Tino Zaehle, Frank Hirth, Hans-Jochen Heinze, Raymond J Dola. Corrigendum: Changing pattern in the basal ganglia: motor switching under reduced dopaminergic drive. Scientific reports. vol 6. 2019-11-20. PMID:27540831. |
corrigendum: changing pattern in the basal ganglia: motor switching under reduced dopaminergic drive. |
2019-11-20 |
2023-08-13 |
Not clear |
| Zade R Holloway, Timothy G Freels, Josiah F Comstock, Hunter G Nolen, Helen J Sable, Deranda B Leste. Comparing phasic dopamine dynamics in the striatum, nucleus accumbens, amygdala, and medial prefrontal cortex. Synapse (New York, N.Y.). 2019-11-20. PMID:30317673. |
midbrain dopaminergic neurons project to and modulate multiple highly interconnected modules of the basal ganglia, limbic system, and frontal cortex. |
2019-11-20 |
2023-08-13 |
mouse |
| A M Muehlmann, S L Wolfman, D P Devin. The role of neurotensin in vulnerability for self-injurious behaviour: studies in a rodent model. Journal of intellectual disability research : JIDR. vol 62. issue 12. 2019-11-15. PMID:30033601. |
abnormal dopaminergic and glutamatergic neurotransmission has been implicated, especially in relation to basal ganglia and mesocorticolimbic circuits. |
2019-11-15 |
2023-08-13 |
rat |
| Mauro Ursino, Chiara Basto. Aberrant learning in Parkinson's disease: A neurocomputational study on bradykinesia. The European journal of neuroscience. vol 47. issue 12. 2019-11-04. PMID:29786160. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by a progressive decline in motor functions, such as bradykinesia, caused by the pathological denervation of nigrostriatal dopaminergic neurons within the basal ganglia (bg). |
2019-11-04 |
2023-08-13 |
human |
| Marta Batllori, Marta Molero-Luis, Aida Ormazabal, Raquel Montero, Cristina Sierra, Antonia Ribes, Julio Montoya, Eduardo Ruiz-Pesini, Mar O'Callaghan, Leticia Pias, Andrés Nascimento, Francesc Palau, Judith Armstrong, Delia Yubero, Juan D Ortigoza-Escobar, Angels García-Cazorla, Rafael Artuc. Cerebrospinal fluid monoamines, pterins, and folate in patients with mitochondrial diseases: systematic review and hospital experience. Journal of inherited metabolic disease. vol 41. issue 6. 2019-11-04. PMID:29974349. |
five out of 29 cases showed predominant dopaminergic signs not attributable to basal ganglia involvement, harboring mutations in different nuclear genes. |
2019-11-04 |
2023-08-13 |
Not clear |
| Nedjeljka Ivica, Ulrike Richter, Joel Sjöbom, Ivani Brys, Martin Tamtè, Per Petersso. Changes in neuronal activity of cortico-basal ganglia-thalamic networks induced by acute dopaminergic manipulations in rats. The European journal of neuroscience. vol 47. issue 3. 2019-10-22. PMID:29250896. |
the basal ganglia are thought to be particularly sensitive to changes in dopaminergic tone, and the realization that reduced dopaminergic signaling causes pronounced motor dysfunction is the rationale behind dopamine replacement therapy in parkinson's disease. |
2019-10-22 |
2023-08-13 |
rat |
| Jin-Zhong Huang, Yi Ren, Yuan Xu, Tao Chen, Terry C Xia, Zhuo-Ri Li, Jian-Nong Zhao, Fei Hua, Shi-Ying Sheng, Ying Xi. The delta-opioid receptor and Parkinson's disease. CNS neuroscience & therapeutics. vol 24. issue 12. 2019-10-14. PMID:30076686. |
although it is known that the major characteristics of pd pathophysiology are the dysfunction of basal ganglia due to injury/loss of dopaminergic neurons in the substantia nigra pars compacta dopaminergic and exhaustion of corpus striatum dopamine, therapeutic modalities for pd are limited in clinical settings up to date. |
2019-10-14 |
2023-08-13 |
Not clear |
| Arjun Tarakad, Joohi Jimenez-Shahe. VMAT2 Inhibitors in Neuropsychiatric Disorders. CNS drugs. vol 32. issue 12. 2019-10-14. PMID:30306450. |
the basal ganglia and dopaminergic pathways play a central role in hyperkinetic movement disorders. |
2019-10-14 |
2023-08-13 |
Not clear |